0      0

AM21-39: Optimization of Progenitor Cell Sources for Hematopoetic Cell Transplantation

Oct 19, 2021 11:15am ‐ Oct 19, 2021 12:15pm

Credits: None available.


The choice of hematopoietic progenitor cell source for transplantation is determined by multiple factors including the underlying disease (hematologic malignancy vs non-malignant hematologic disorder), conditioning regimen (myeloablative vs reduced intensity), and type of donor. Data from the prospective randomized Blood and Marrow Transplant Clinical Trial Network 0201 trial regarding bone marrow versus peripheral blood stem cell for hematopoietic cell transplantation, the declining quality of bone marrow harvests over the past two decades, and improved prevention of chronic graft versus host disease will be addressed in this context. This presentation will also address quality improvement strategies for the collection of bone marrow and innovative approaches for optimizing progenitor cell collections by apheresis, including the use of novel agents such as plerixafor and chemokine ligand 2 (CXCL2), to enhance progenitor cell yield and maximize donor safety.

Moderator & Speaker(s):



Credits: None available.

You must be logged in and own this session in order to post comments.